Penwest Pharmaceuticals Co

Penwest Pharmaceuticals — Proxy Contest (May 2009)

29 slides from Penwest Pharmaceuticals's proxy contest presentation, May 27, 2009

  1. Slide 1: A Simple Choice for Our Investors: Build Shareholder Value or Call it Quits

    (Nasdaq: PPCO) May 2009 A Simple Choice for Our Investors: Build Shareholder Value or Call it Quits

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The matters discussed herein contain forward-looking statements that involve risks and uncertainties, which may cause the actual results in future periods to be materially different from any future performance suggested herein. For this purpose, any statements contained he

  3. Slide 3: Information Concerning Participants

    Information Concerning Participants Information required to be disclosed with regard to the Company's directors, director nominees, officers and employees who, under the rules of the Securities and Exchange Commission (the "SEC"), are considered to be "participants" in the Company's solicitation of

  4. Slide 4: Penwest's Strategy

    Penwest's Strategy Board unanimously believes that our strategy can build shareholder value in the short-term and prepare the Company for long-term growth by: Maximizing Opana revenues in partnership with Endo Advancing A0001 to establish proof of concept for safety and biological activity Monetizin

  5. Slide 5: Why are We Fighting?

    Why are We Fighting? Strongly believe narrowed strategy for 2009 is right one to build shareholder value in the short-term and prepare the Company for long-term growth Stopping now would prematurely cap potential upside for shareholders May even reduce the value through loss of access to tax credits

  6. Slide 6: Our Board

    OUR BOARD

  7. Slide 7: Board Continuous Improvement

    Board Continuous Improvement Board Continuous Improvement - -Directors highlighted in red have been added since 2005 *Dates are as of annual meeting; 2009 assumes election of Company slate

  8. Slide 8: Highly Qualified Board Focused on Building Shareholder Value

    Highly Qualified Board Focused on Building Shareholder Value Since 2005, conscious effort to build a Board of experienced, skilled directors to match the Company's strategy If our nominees are elected, Board will reflect valuable combination of scientific, regulatory, medical, commercial, strategic

  9. Slide 9: Director nominee W. James O'Shea

    Director nominee W. James O'Shea experienced pharmaceutical executive; highly-respected, independent industry expert Strong track record in hands-on executive and operating roles at public companies Former President & COO, Vice Chairman, Sepracor Inc. During his tenure, annual revenues grew from $22

  10. Slide 10: Board Not Opposed to Considering Alternative Views

    Board Not Opposed to Considering Alternative Views Nomination of Joe Edelman reflects balanced, reasonable approach Dissident views will be represented in decision-making Facts about Edelman: Long-term Penwest shareholder Has previously offered constructive input about operations and R&D program Int

  11. Slide 11: Experienced Board with Right Combination of Skills

    Experienced Board with Right Combination of Skills Paul E. Freiman Lead Director from 1997 to 2005; Chairman since 2005 Chair of Nominating and Governance Committee President of consulting firm ThirdAge Pharma LLC Former President & CEO, Neurobiological Technologies, Inc. Former Chairman and CEO of

  12. Slide 12: Experienced Board with Right Combination of Skills

    Jennifer Good President & CEO and Management Director since 2006 Former President, COO and CFO, Penwest 2005-2006 Former CFO, Penwest 1997-2005 Certified Public Accountant David Meeker, M.D. Independent Director since 2007 Chair of Scientific Review Committee Executive Vice President, Therapeutics,

  13. Slide 13: Experienced Board with Right Combination of Skills

    Anne VanLent Independent Director since 1998 Chair of Audit Committee President of AMV Advisors, strategic planning and financial services consulting company to emerging growth life sciences companies Former Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. Former Pr

  14. Slide 14: Proxy Contest

    PROXY CONTEST

  15. Slide 15: Tang's Track Record With Other Investments Offers Warning Signs

    Tang's Track Record With Other Investments Offers Warning Signs Vanda: After launching a proxy fight against Vanda in February to force the liquidation of Vanda, Tang Capital abandoned its campaign earlier this month following announcement that the FDA had granted marketing approval of Vanda's schiz

  16. Slide 16: Tang's Conduct Raises Serious Concerns

    Tang's Conduct Raises Serious Concerns Tang's conduct with Penwest raises serious concerns about his suitability to be a director Tang has twice offered in writing to give the Company's directors personally the A0001 asset and business opportunity for their own financial benefit without their having

  17. Slide 17: Penwest Board is Committed to Good Corporate Governance

    Penwest Board is Committed to Good Corporate Governance Penwest's Board is committed to good corporate governance and pay practices while protecting the interests of all shareholders Listens to Shareholders We have recommended that shareholders vote to elect as a director Joseph Edelman, a member of

  18. Slide 18: By-Law Amendments & Litigation = Seeking Immediate Control

    By-Law Amendments & Litigation= Seeking Immediate Control The Dissidents' proposals include: A resolution requesting that the Board immediately wind down substantially all of the Company's operations A resolution to amend the Company's by-laws to require approval of 75% or 81% of the directors for c

  19. Slide 19: Proposal to Wind Down Operations Is Detrimental to Shareholders

    Proposal 6 to Wind Down Operations Is Detrimental to Shareholders The proposal calls "for the board of directors of the Company to take prompt and thoughtful action to preserve shareholder value by immediately winding down substantially all of the Company's operations so that the full value of the O

  20. Slide 20: Proposals 5-A and 5-B Promote Veto Power

    Proposals 5-A and 5-B Promote Veto Power "The board of directors shall not take any of the following actions, or delegate to any officer, employee or agent of the corporation the authority to take any such actions, without the approval of 75% or more of the directors then in office, unless such acti

  21. Slide 21: Dissident Proposal to Set the Annual Meeting Date

    Dissident Proposal to Set the Annual Meeting Date The proposal requires annual meetings to be held on April 30th each year Our Board believes that adoption of this proposal would not be in the best interests of Penwest or our shareholders Among other things, a mandatory April 30 annual meeting date

  22. Slide 22: Our Strategy

    OUR STRATEGY

  23. Slide 23: Penwest 2009 Strategy

    Penwest 2009 Strategy Focused strategy to drive shareholder value. The Company's plan for 2009 consists of the following key components: Maximize Opana revenues in partnership with Endo Complete ex-U.S. outlicensing of Opana ER Advance A0001 to establish proof of concept for safety and biological ac

  24. Slide 24: 2009 Value Drivers

    2009 Value Drivers We believe that by pursuing this strategy, we can enter 2010: As a profitable and cash flow positive Company Opana ER contributing at the full royalty rate Additional assets out licensed to create incremental long term growth On a path towards demonstrating proof of concept around

  25. Slide 25: Opposing Strategy: Vote for Shareholder Value or Vote to Call It Quits

    Opposing Strategy Vote for Shareholder Value or Vote to Call It Quits Tang/Edelman Strategy: "...immediately winding down substantially all of the Company's operations..." Board unanimously disagrees for the following reasons: Leaves assets on the table which have not realized their full value (Opan

  26. Slide 26: Opposing Strategy: Risk of losing access to NOL tax carryforwards

    Opposing Strategy Risk of losing access to the majority of our $91 million of available net operating loss tax carryforwards In 2008, Perceptive triggered a change in control under tax rules, which cost us access to $123 million of NOL's and an additional loss of $7 million in tax credits Under Sec

  27. Slide 27: Opposing Strategy: Risk of losing our NASDAQ listing

    Opposing Strategy Risk of losing our NASDAQ listing because Penwest would be a "public shell" A public shell is defined as "A company with no or nominal operations and either no or nominal assets, assets consisting solely of cash and cash equivalents..." Company would likely be delisted, impairing s

  28. Slide 28: Conclusion

    Conclusion Board unanimously believes that our strategy can build shareholder value in the short-term and prepare the Company for long-term growth by: Maximizing Opana revenues in partnership with Endo Advancing A0001 to establish proof of concept for safety and biological activity Monetizing the va

  29. Slide 29: Penwest

    AaFenwest (Nasdaq: PPCO) May 2009 ~aPenwest

Penwest Pharmaceuticals — Proxy Contest (May 2009) on 6ix